MAPLE GROVE, Minn., Dec. 19, 2016 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a Minnesota-based pharmaceutical company today announced that it has entered into a definitive agreement under which Sandoz Inc. has acquired its AmLactin® brand family of skin care brands. This agreement is part of Upsher-Smith's strategy to focus with even greater precision on its mission of delivering high-value, high-quality generics and novel therapies to customers.
Specific terms related to the deal have not been disclosed. Piper Jaffray & Company served as exclusive advisor to Upsher-Smith on this transaction.
Upsher-Smith Laboratories, Inc., founded in 1919, is a growing, fully integrated pharmaceutical company dedicated to its mission of delivering high-value, high-quality therapies and solutions which measurably improve individuals' lives. As a family-owned pharmaceutical company, we are able to adapt and thrive in a dynamic healthcare environment. Our world is constantly evolving, and we are continually adapting to the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. Where there is a need, we will work to deliver solutions that simplify access to treatment, deliver better health outcomes, and enhance life. Upsher-Smith has a particular focus on developing therapies for people living with central nervous system (CNS) conditions, such as seizure disorders. For more information, visit www.upsher-smith.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/upsher-smith-divests-amlactin-brand-family-300381091.html
SOURCE Upsher-Smith Laboratories, Inc.